High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: The Atherosclerosis Risk in Communities (ARIC) study - 10/12/14
, Sunil K. Agarwal, MD, PhD c, Christie M. Ballantyne, MD d, e, Maria Eberg, MSc a, Ron C. Hoogeveen, PhD d, e, Rachel R. Huxley, DPhil f, Laura R. Loehr, MD, PhD g, Vijay Nambi, MD, PhD d, e, h, Elsayed Z. Soliman, MD, MSc, MS i, Alvaro Alonso, MD, PhD bRiassunto |
Introduction |
Structural changes in the heart are known risk factors for atrial fibrillation (AF). An association between high-sensitivity cardiac troponin T (hs-cTnT), a marker of myocardial cell damage measured with a high-sensitivity assay, and the risk of AF could have implications for AF risk stratification.
Objective |
To estimate the association between hs-cTnT and the risk of incident AF in the ARIC study, a prospective cohort of middle-aged adults from 4 US communities.
Methods |
Study included 10,584 participants (mean age 62.7 years) free of AF in 1996 to 1998 and followed through 2008. Atrial fibrillation was defined using International Classification of Diseases codes from hospitalizations and death certificates. Participants with undetectable hs-cTnT levels (58%) were assigned the lower limit of measurement (5 ng/L). Net reclassification improvement was used to examine the discriminative ability of hs-cTnT for 10-year AF risk prediction (categories: <5%, 5%-15%, and >15%).
Results |
A total of 920 incident AF cases were observed for 109,227 person-years. After adjustment, a 1-SD difference in ln(hs-cTnT) was associated with a hazard ratio of 1.16 (95% CI 1.10-1.23). Compared with those with undetectable levels, participants with hs-cTnT ≥14 ng/L had a hazard ratio of 1.78 (95% CI 1.43-2.24). Addition of hs-cTnT to known AF predictors did not increase the c statistic appreciably (0.756 vs 0.758) or improve risk stratification (net reclassification improvement 0.4%, 95% CI −1.4% to 2.3%).
Conclusions |
High-sensitivity cTnT level is associated with an increased incidence rate of AF but did not improve risk stratification.
Il testo completo di questo articolo è disponibile in PDF.Mappa
Vol 169 - N° 1
P. 31 - Gennaio 2015 Ritorno al numero
Articolo precedente
- Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial
- Christopher B. Granger, Renato D. Lopes, Michael Hanna, Jack Ansell, Elaine M. Hylek, John H. Alexander, Laine Thomas, Junyuan Wang, M. Cecilia Bahit, Freek Verheugt, Jack Lawrence, Denis Xavier, Lars Wallentin
- Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke
- Ann Marie Navar-Boggan, Jennifer A. Rymer, Jonathan P. Piccini, Wassim Shatila, Lauren Ring, Judith A. Stafford, Sana M. Al-Khatib, Eric D. Peterson
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?